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Fetal Release of Copeptin in Response to
Maternal Oxytocin Administration
A Randomized Controlled Trial
Sven Wellmann, MD, Andrea Koslowski, Katharina Spanaus, MD, Roland Zimmermann, MD,
and Tilo Burkhardt, MD
OBJECTIVE: To test whether an oxytocin challenge test
raises neonatal levels of copeptin, the C-terminal portion
of proarginine vasopressin, a sensitive stress marker
elevated in neonates born by vaginal delivery as opposed
to elective cesarean delivery.
METHODS: In a randomized controlled trial in women
with a singleton pregnancy undergoing elective cesarean
delivery at greater than 36 weeks of gestation and no
contractions or rupture of membranes, we compared
arterial umbilical cord plasma concentrations of copeptin
between neonates exposed to an oxytocin challenge test
before elective cesarean delivery and those administered
saline infusion (placebo group). Women randomized to an
oxytocin challenge test received 5 international units/500
mL oxytocin Ringer lactate infused at a rate of 12 mL/h and
doubled every 10 minutes until it induced three uterine
contractions per 10-minute interval, at which point it was
discontinued. Neonatal copeptin levels were the primary
endpoint. Secondary endpoints included biochemical and
physiologic parameters of fetal and maternal well-being.
RESULTS: From January 2012 to October 2012 and from
September 2013 to January 2015, 78 women underwent
an oxytocin challenge test and 78 placebo infusion, of
whom 12 and 11, respectively, were excluded as a result
of insufficient blood sample volume for analysis. Umbil-
ical cord plasma copeptin levels [median (range)] were
higher in neonates who underwent an oxytocin chal-
lenge test than those who underwent placebo infusion:
22.2 (3.22–2,319) compared with 7.39 (2.5–344.6) pmol/L
(P,.001). There were no statistically significant differen-
ces between the two groups in secondary outcomes.
CONCLUSION: Oxytocin challenge test-induced con-
tractions before elective cesarean delivery trigger fetal
copeptin release.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov,
https://clinicaltrials.gov, NCT01962701.
(Obstet Gynecol 2016;128:699–703)
DOI: 10.1097/AOG.0000000000001594
Copeptin is a nonspecific but highly sensitiveplasma indicator of stress and a more sensitive
marker than cortisol.1,2 It derives from the prohormone
of arginine vasopressin (AVP) and is secreted in equi-
molar amounts to AVP from the pituitary into the
circulatory system.3 Pulsatile secretion, platelet bind-
ing, and a short half-life make direct measurement of
AVP unfeasible in the clinical setting. Copeptin, how-
ever, remains stable in blood collection tubes and can
readily be measured by sandwich immunoassay.4
Vaginal delivery of a healthy newborn provokes
a unique surge in copeptin plasma concentration
incommensurable with child or adult levels measured
in any other situation.5–8 In contrast, newborns deliv-
ered by elective cesarean delivery without preceding
labor have low copeptin concentrations at birth unless
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other stressors are present, including chorioamnionitis
or fetal growth restriction.7,9 In newborns delivered
by cesarean delivery after the onset of labor, copeptin
concentrations fall between these two extremes.5,10
The specific stressors inducing copeptin release
during vaginal delivery remain unknown. Brief epi-
sodes of hypoxia suffice to trigger copeptin release
in vivo.11,12 Such episodes are occasionally observed
during labor where they manifest as late decelerations
on the cardiotocogram. However, in the absence of an
abnormal or indeterminate cardiotocogram, hard evi-
dence is lacking that labor per se causes a fetal stress
response.
We conducted a prospective, randomized con-
trolled trial in women scheduled for elective cesarean
delivery to test whether the mild labor—no more than
three contractions within 10 minutes—induced by an
oxytocin challenge test suffices per se in the absence
of any other identified stressor, in particular hypoxia,
to raise neonatal copeptin levels.
MATERIALS AND METHODS
Enrollment ran from January through October 2012
and from September 2013 through January 2015. The
institutional review board approved the study pro-
vided safety was assessed after enrolling 30 patients
per group. No safety issues were detected and
enrollment continued. The trial was registered at Clin-
icalTrials.gov, number NCT01962701.
The inclusion criteria were singleton pregnancy,
elective cesarean delivery without preceding contrac-
tions or rupture of the membranes after completed 36
weeks of gestation, and absence of a contraindication
to oxytocin. Exclusion criteria in the fetus were
chromosomal aberration, malformation, fetal growth
restriction, placenta previa, and infection. Maternal
exclusion criteria were substance abuse, infection,
hypertension, preeclampsia, diabetes type I or II,
and autoimmune disease (eg, antiphospholipid syn-
drome, renal disease, or a history of more than one
previous cesarean delivery). No mother in either
group had received nonsteroidal anti-inflammatory
drugs or vasoactive drugs during pregnancy.
The day before undergoing elective cesarean
delivery, all eligible women were asked for their
informed consent. On the day of elective cesarean
delivery, after admission to the delivery room and
placement of an intravenous line, women were
randomized in a one-to-one ratio using a random
number generator to infusion of either oxytocin
(oxytocin challenge test group) or saline (placebo
group). Oxytocin at 5 international units/500 mL
Ringer lactate was infused at a rate of 12 mL/h and
doubled every 10 minutes until it induced three
uterine contractions per 10-minute interval, at which
point the oxytocin administration was discontinued.
Arterial cord blood samples were collected imme-
diately after delivery into ethylenediamine pentaacetic
acid tubes, centrifuged, and the plasma was stored at
280°C. Copeptin was measured in three batches
using the BRAHMS KRYPTOR automated research
sandwich immunoluminometric assay, as described
previously.5 Delay in introducing the latest and highly
sensitive BRAHMS copeptin assay onto the Swiss
market led to an enrollment gap of 1 year, because
our aim was to measure all batches with the new
assay, including the samples from the first enrollment
period.
Neonatal copeptin levels were the primary end-
point. Secondary endpoints included biochemical and
physiologic parameters of fetal and maternal well-
being, in particular respiratory morbidity, oxytocin
challenge test acceptability, and the noncontinuation
of labor postoxytocin challenge test. We performed
all statistical analyses in STATA 10.1 using the Mann-
Whitney test and x2 test or Fisher exact test as appro-
priate to compare groups at a 95% significance level.
According to the interim analysis after enrolling
30 patients per group, the sample size was set to 70
per group with a 10% sample error rate, which would
allow us to detect a difference in copeptin concen-
trations of 21 pmol/L (from 9 to 30 pmol/L) with a of
0.05 and power of 90%.
RESULTS
From January 2012 to October 2012 and from
September 2013 to January 2015, 78 women under-
went an oxytocin challenge test and 78 placebo
infusion, of whom 12 and 11, respectively, were
excluded as a result of insufficient blood sample
volume for analysis (Fig. 1). Indications for elective
cesarean delivery were previous delivery and cesar-
ean delivery on demand. Mean maternal age, mater-
nal parity, rate of previous cesarean delivery, and
neonatal sex were similar in both groups (Table 1).
The time interval between discontinuation of the
oxytocin challenge test infusion and delivery was 71
(28–342) minutes [median (range)]. Umbilical cord
plasma copeptin concentrations were significantly
higher in the oxytocin challenge test group: 22.15
(3.22–2,319) compared with 7.39 (2.47–344) pmol/L
(P,.001; [median (range)]) (Fig. 2).
In no case did the oxytocin challenge test have to
be interrupted because of painful contractions or
a nonreassuring fetal heart rate pattern nor did labor
continue after the oxytocin challenge test was stopped.
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No neonate in either group showed signs of asphyxia;
there were no instances of low umbilical artery pH, low
Apgar score, or elevated umbilical artery lactate
(Table 1). Only 36 of 66 (55%) women in the oxytocin
challenge test group noticed the contractions.
DISCUSSION
The main finding of this randomized trial is that
copeptin, a surrogate marker of plasma vasopressin, is
markedly increased in the umbilical cord blood of
neonates exposed to oxytocin challenge test-induced
contractions before elective cesarean delivery. The
threefold difference compared with the placebo group
was unassociated with any evidence of acidosis.
Unexpectedly, plasma copeptin levels were
spread over a wide range in both groups (Fig. 2). Even
a few control neonates had fairly high copeptin levels,
perhaps as a result of unrecognized contractions
before enrollment. This possibility is supported by
the fact that only half the women in the oxytocin
challenge test group noticed their oxytocin challenge
test-induced contractions.
Mild uterine contractions lead to brief pO2 drops
in the fetus, often without noticeable changes in fetal
heart rate tracing.13–15 Animal data indicate a direct
and dose-dependent link between uterine contractions
and fetal arterial pO2 changes16,17 and a relationship
between arterial pO2 and plasma AVP in fetal
sheep.18,19 Even changes in fetal arterial pO2 as small
as 2.5 mm Hg were sufficient to release corticotropin,
an effector hormone of AVP and corticotropin-
releasing hormone.20 However, it remains open
whether such a link among mild uterine contractions,
fetal pO2 changes, and copeptin–AVP release might
explain our observations reported here.
Fig. 1. Study design and enrollment. OCT, oxytocin chal-
lenge test.
Wellmann. Copeptin Response to Oxytocin Challenge. Obstet
Gynecol 2016.
Table 1. Baseline Characteristics and Neonatal
Outcome Parameters of the Oxytocin
Challenge and Placebo Groups
Variable
Oxytocin
Challenge
(n566)
Placebo
(n567) P
Maternal age (y) 33.765.0 33.565.9
Multiparous 40 (61) 46 (69)
Race
White 60 (91) 56 (84)
Other 6 (9) 11 (16)
Indications for cesarean
delivery
Previous cesarean
delivery
33 (50) 39 (58)
Cesarean delivery on
demand
30 (45.5) 23 (34)
Other* 3 (4.5) 5 (8)
Gestational age (d) 270.565.0 269.364.4
Birth weight (g) 3,3496470 3,2646478
Birth weight percentile 59.4629.1 56.1629.6
Neonatal sex
Female 31 (47) 39 (58)
Male 35 (53) 28 (42)
Umbilical artery pH 7.3260.06 7.3360.04 .71
Umbilical artery lactate
(mmol/L)
2.1560.74 2.1860.6 .80
5-min Apgar score 9.160.4 9.060.5 .32
Respiratory distress 2 (3) 4 (6) .41†
Postnatal neonatal
weight loss (%)
7.262.3 7.262.0 1.0
Data are mean6standard deviation or n (%) unless otherwise
specified.
* Retinopathy, spondylopathy, previous third-degree perineal tear,
urinary incontinence, estimated fetal weight greater than the
95th percentile.
Data were compared using Student t test for continuous data and x2
test or †Fisher exact test for categorical data.
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Copeptin reflects vasopressin secretion. Animal
studies suggest that vasopressin regulates lung fluid
secretion and reabsorption.21–23 However, the mecha-
nism involved remains uncertain. In fetal sheep, Albu-
querque et al24 found no evidence that the vasopressin-2
receptor mediated a reduction in lung fluid production;
they suggested the effect was instead mediated by the
vasopressin-1 receptor. In the neonatal rat, on the other
hand, Guetta et al25 showed that the vasopressin-2
receptor regulates the increase in active sodium trans-
port and alveolar fluid clearance from the lung.
Compared with vaginal birth or cesarean delivery
after the onset of labor, elective cesarean delivery
performed before the onset of labor and rupture of the
membranes carries an increased risk of neonatal
respiratory morbidity such as respiratory distress
syndrome or transient tachypnea.26–28 Hence, it has
been proposed that corticosteroids be administered
(prophylactically) between 37 and 38 weeks of gesta-
tion before term elective cesarean delivery to reduce
neonatal respiratory morbidity.29,30 Despite the evi-
dence of respiratory benefit29–31 and the absence, as
far as is known, of adverse long-term outcomes,32 seri-
ous reservations persist.33,34
The present study was powered for the primary
endpoint, namely copeptin at birth. None of the
results for parameters of fetal or maternal well-being
were significant. Thus, no conclusions can be drawn
on the secondary endpoint of respiratory morbidity.
However, the excellent acceptance of the oxytocin
challenge test and the absence of safety issues in this
trial, in particular that labor did not progress after
withdrawal of oxytocin infusion, favor the project of
a larger trial geared to neonatal respiratory morbidity
as the primary endpoint. A power calculation based
on the observed proportions of respiratory morbidity
revealed that a sample size of 1,000 cases and 1,000
controls would be necessary to detect a clinically
relevant difference with 90% power, that is, a reduc-
tion in neonatal respiratory morbidity from a rate of
6% to 3%.
The oxytocin challenge test has been a standard
procedure for many decades in pregnancies with
suspected placental insufficiency, but to our knowl-
edge, we are the first to perform a study investigating
the effect of an oxytocin challenge test on an appro-
priately grown fetus shortly before elective cesarean
delivery (search was conducted on MEDLINE, avail-
able through PubMed to December 2015 with the
following search terms: oxytocin challenge, cesarean).
We hypothesize that the mild uterine contractions
induced by the oxytocin challenge test suffice to
upregulate a variety of stress hormones in the fetus,
principally corticosteroids, that may help to improve
primary adaptation to an air-breathing environment.
More particularly, there is evidence that AVP itself,
which we measured using its surrogate marker co-
peptin, specifically supports adaptation of the lung,
including alveolar fluid reabsorption and surfactant
secretion.21,35,36
In conclusion, oxytocin challenge test-induced con-
tractions suffice to elevate fetal levels of copeptin and
inferentially those of AVP. This result is an argument in
favor of a trial designed to lower neonatal respiratory
morbidity after elective cesarean delivery by a preemp-
tive intervention that increases fetal copeptin levels.
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